Abstract:
PURPOSE: A composition containing extract isolated from lactic acid bacteria culture liquid is provided to suppress IL-6 secretion and to treat inflammatory diseases and cancer. CONSTITUTION: A composition for treating inflammatory diseases contains extract of lactic acid bacteria culture liquid. The lactic acid bacteria are Lactobacillus, Lactococcus, Leukonostoc, Pediococcus, or Bifidobacteria. The extract contains supernatant of the culture liquid except for the bacteria. The supernatant contains heat resistant ingredients. A composition for treating cancer contains the extract. A composition for treating thrombokinesis-related diseases contains the extract. A method for treating inflammatory diseases or cancer comprises a step of administering the extract.
Abstract:
PURPOSE: A pharmaceutical composition containing an inhibitor of inducible nitric oxide synthase is provided to treat severe inflammatory respiratory diseases. CONSTITUTION: A pharmaceutical composition for treating or preventing severe inflammatory diseases contains an inhibitor of inducible nitric oxide synthetase as an active ingredient. The severe inflammatory diseases are severe asthma or chronic obstructive lung diseases. The severe inflammatory disease is prevented or treated by administering to topical or whole body of mammal.
Abstract:
The present invention relates to a method for differentiating embryonic stem cells into hepatocytes by treating the embryonic stem cells with hepatocyte-derived microvesicles. The microvesicles of the present invention contains protein, mRNA, or the like which is specific hepatocytes, thereby simply and efficiently differentiating into hepatocytes using cell membrane-protected cytoplasm without an insertion of other genes using a vector. Accordingly, the microvesicles enables simple and efficient differentiation into hepatocytes. [Reference numerals] (AA) Microvesicles;(BB) DIO fluorescence;(CC) Fusing
Abstract:
PURPOSE: A pharmaceutical formulation for respiratory administration for treating or preventing respiratory inflammation disease is provided to suppress respiratory inflammation. CONSTITUTION: A pharmaceutical formulation for respiratory administration for treating or preventing respiratory inflammation diseases contains pharmaceutically or veterinarily acceptable carrier, peptide which functions in formyl peptide receptor(FPR) or analogous receptor thereof or pharmaceutically acceptable salt. The peptide comprises an amino acid sequence selected from sequence numbers 1-28. The carrier is vapor, liquid or microparticle powder.